The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LP-300 as a potential first-in-class combination agent with tyrosine kinase inhibitors (TKIs) in non-smoker lung adenocarcinoma.
 
Aditya Kulkarni
Employment - Lantern Pharma
Research Funding - Lantern Pharma
 
Aulma Parker
Employment - BioNumerik; Not known; Seagen; Syneos Health
Consulting or Advisory Role - Lantern Pharma
Research Funding - BioNumerik; Lantern Pharma; Not known
 
Kamwing Jair
Employment - Not known
Research Funding - Not known
 
Pavankumar Petluru
Employment - Not available
 
Xinghai Chen
No Relationships to Disclose
 
Harry Kochat
Stock and Other Ownership Interests - BioNumerik Pharmaceuticals, Inc.
Consulting or Advisory Role - Lantern Pharmaceuticals, Inc.
 
Frederick H. Hausheer
Employment - WuXi AppTec
Leadership - WuXi AppTec
Stock and Other Ownership Interests - WuXi AppTec
 
Umesh Kathad
Employment - Lantern Pharma
Research Funding - Lantern Pharma
 
Kishor Bhatia
Employment - Lantern Pharma
Research Funding - Lantern Pharma
 
Kerry Barnhart
Employment - Lantern Pharma
 
Panna Sharma
Employment - Lantern Pharma
Leadership - Lantern Pharma